Leerink Partnrs Issues Positive Estimate for argenx Earnings

argenx SE (NASDAQ:ARGX) – Analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of argenx in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $4.36 for the year, up from their previous forecast of $2.90. The consensus estimate for argenx’s current full-year earnings is $2.78 per share. Leerink Partnrs also issued estimates for argenx’s Q4 2024 earnings at $3.33 EPS, FY2025 earnings at $12.40 EPS, FY2026 earnings at $20.91 EPS and FY2027 earnings at $27.22 EPS.

Several other equities research analysts have also issued reports on ARGX. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Citigroup lifted their price objective on shares of argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Evercore ISI increased their target price on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. JMP Securities lifted their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Finally, JPMorgan Chase & Co. increased their price objective on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Trading Down 2.0 %

Shares of NASDAQ ARGX opened at $657.97 on Friday. The business has a 50-day moving average of $636.51 and a 200-day moving average of $574.93. The firm has a market capitalization of $39.98 billion, a price-to-earnings ratio of -747.69 and a beta of 0.58. argenx has a 12 month low of $349.86 and a 12 month high of $678.21.

Hedge Funds Weigh In On argenx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Whipplewood Advisors LLC bought a new stake in shares of argenx in the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its holdings in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp grew its position in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of argenx during the fourth quarter valued at approximately $66,000. Finally, Nkcfo LLC bought a new position in shares of argenx during the fourth quarter valued at approximately $68,000. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.